Nevirapine, stavudine and lamivudine pharmacokinetics in African children on paediatric fixed-dose combination tablets

AIDS

Volumn 22, Issue 5, 2008, Pages 557-565

  L'Homme, Rafaëlla F A ^a   Kabamba, Desiré ^b   Ewings, Fiona M ^c   Mulenga, Veronica ^b   Kankasa, Chipepo ^b   Thomason, Margaret J ^c   Walker, A Sarah ^c   Chintu, Chifumbe ^b   Burger, David M ^a   Gibb, Diana M ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY TEACHING HOSPITAL   (Zambia)

^c MEDICAL RESEARCH COUNCIL   (United Kingdom)

Author keywords

Africa; Fixed dose combination; Lamivudine; Nevirapine; Paediatric; Pharmacokinetics; Stavudine

Indexed keywords

AMOXICILLIN; ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; FANSIDAR; FERROUS SULFATE; LAMIVIR S; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; PARACETAMOL;

ADOLESCENT; ANTIBIOTIC PROPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG ERUPTION; DRUG WITHDRAWAL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; PATIENT COMPLIANCE; PRIORITY JOURNAL; SIDE EFFECT;

ADOLESCENT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; AREA UNDER CURVE; BODY WEIGHT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; DRUG MONITORING; FEMALE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; LAMIVUDINE; MALE; NEVIRAPINE; REVERSE TRANSCRIPTASE INHIBITORS; STAVUDINE; ZAMBIA;

EID: 43149106475     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3282f4a208     Document Type: Article

References (21)

1. WHO/UNAIDS/UNICEF. Scaling up priority HIV/AIDS interventions in the health sector: towards universal access. Progress report, April 2007. Available at: www.who.int. Accessed: November 2007.
2. Havens PL, Gibb DM. Increasing antiretroviral drug access for children with HIV infection. Pediatrics 2007; 119:838-845.
3. Ellis JC, L'homme RFA, Ewings FM, Mulenga V, Bell F, Chileshe R, et al. Nevirapine concentrations in HIV-infected children treated with divided fixed-dose combination antiretroviral tablets in Malawi and Zambia. Antivir Ther 2007; 12:253-260.
4. de Vries-Sluijs TE, Dieleman JP, Arts D, Huitema AD, Beijnen JH, Schutten M, van der Ende ME. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42:599-605.
5. Verweel G, Sharland M, Lyall H, Novelli V, Gibb DM, Dumont G, et al. Nevirapine use in HIV-1-infected children. AIDS 2003; 17:1639-1647.
6. World Health Organization. Preferred antiretroviral medicines for treating and preventing HIV infection in younger children, August 2007. Available at: www.who.int. Accessed: November 2007
7. L'homme RFA, Dijkema T, Warris A, van der Ven AJAM, Gibb DM, Burger DM. Pharmacokinetics of two generic fixed-dose combinations for HIV-infected children (Pedimune Baby & Pedimune Junior) are similar to the branded products in healthy adults. J Antimicrob Chemother 2007; 59:92-96.
8. Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer 2001; 85:23-28.
9. Hollanders RMW, van Ewijk-Beneken Kolmer EWJ, Burger DM, Wuis EW, Koopmans PP, Hekster YA. Determination of nevirapine, an HIV-1 nonnucleoside reverse transcriptase inhibitor, in human plasma by reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 2000; 744:65-71.
10. Verweij-van Wissen CP, Aarnoutse RE, Burger DM. Simultaneous determination of the HIV nucleoside analogue reverse transcriptase inhibitors lamivudine, didanosine, stavudine, zidovudine and abacavir in human plasma by reversed phase high performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2005; 816:121-129.
11. Cole TJ, Freeman JV, Preece MA. British 1990 growth reference centiles for weight, height, body mass index and head circumference fitted by maximum penalized likelihood. Stat Med 1998; 17:407-429.
12. Wade AM, Ades AE. Age-related reference ranges: significance tests for models and confidence intervals for centiles. Stat Med 1994; 13:2359-2367.
13. La Porte CJL, Back DJ, Blaschke T, Boucher CAB, Fletcher CV, Flexner C, et al. Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006; 3:4-14.
14. Van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JMA, et al. The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. AIDS 2000; 14:F77-F82.
15. Menson EN, Walker AS, Sharland M, Wells C, Tudor-Williams G, Riordan FAI, et al. Underdosing of antiretrovirals in UK and Irish children with HIV as an example of problems in prescribing medicines to children, 1997-2005: cohort study. BMJ 2006; 332:1183-1187.
16. Bergshoeff A, Burger D, Verweij C, Farrelly L, Flynn J, Le Prevost M, et al. Plasma pharmacokinetics of once- versus twice-daily lamivudine and abacavir: simplification of combination treatment in HIV-1-infected children (PENTA-13). Antivir Ther 2005; 10:239-246.
17. Burger DM, Verweel G, Rakhmanina N, Verwey-Van Wissen CP, La Porte CJ, Bergshoeff AS, et al. Age-dependent pharmacokinetics of lamivudine in HIV-infected children. Clin Pharmacol Ther 2007; 81:517-520.
18. Chokephaibulkit K, Plipat N, Cressey TR, Frederix K, Phongsamart W, Capparelli E, et al. Pharmacokinetics of nevirapine in HIV-infected children receiving an adult fixed-dose combination of stavudine, lamivudine and nevirapine. AIDS 2005; 19:1495-1499.
19. Corbett A, Hosseinipour M, Nyirenda J. Pharmacokinetics between trade and generic liquid and split tablet formulations of lamivudine, stavudine and nevirapine in HIV infected Malawian children. In: 45th International Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, USA; 16-19 December 2005. Abstract 1106.
20. Kappelhoff BS, Van Leth F, MacGregor TR, Lange J, Beijnen JH, Huitema AD, 2NN Study Group. Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study. Antivir Ther 2005; 10:145-155.
21. Violari A, Cotton M, Gibb DM. Antiretroviral therapy initiated before 12 weeks of age reduces early mortality in young HIV-infected infants: evidence from the Children with HIV Early Antiretroviral Therapy (CHER) Study. In: 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia; 22-25 July 2007. Abstract WESS 103.